Wilson Marc 4
4 · Crinetics Pharmaceuticals, Inc. · Filed Jan 4, 2024
Insider Transaction Report
Form 4
Wilson Marc
CFO
Transactions
- Exercise/Conversion
Common Stock
2024-01-02$9.28/sh+10,000$92,800→ 106,055 total - Exercise/Conversion
Non-qualified stock option (Right to Buy)
2024-01-02−10,000→ 51,185 totalExercise: $9.28Exp: 2028-05-24→ Common Stock (10,000 underlying) - Sale
Common Stock
2024-01-02$35.47/sh−10,000$354,700→ 96,055 total
Footnotes (4)
- [F1]Includes 454 shares acquired under the Issuer's Employee Stock Purchase.
- [F2]The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan.
- [F3]The common stock was sold by the Reporting Person in open market transactions on the transaction date with a volume weighted average sales price of $35.47 per share. The range of sales prices on the transaction date was $34.41 to $36.07 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
- [F4]1/48th of the shares subject to the option vested on June 25, 2018, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.